Analytical Data
-
基因名
ERG
- Application
-
别名
ERG；Transcriptional regulator ERG
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P11308
-
表达区间
2-479aa
-
氨基酸序列
MASMTGGQQMGRGHHHHHHENLYFQGSASTIKEALSVVSEDQSLFECAYG TPHLAKTEMTASSSSDYGQTSKMSPRVPQQDWLSQPPARVTIKMECNPSQ VNGSRNSPDECSVAKGGKMVGSPDTVGMNYGSYMEEKHMPPPNMTTNERR VIVPADPTLWSTDHVRQWLEWAVKEYGLPDVNILLFQNIDGKELCKMTKD DFQRLTPSYNADILLSHLHYLRETPLPHLTSDDVDKALQNSPRLMHARNT GGAAFIFPNTSVYPEATQRITTRPDLPYEPPRRSAWTGHGHPTPQSKAAQ PSPSTVPKTEDQRPQLDPYQILGPTSSRLANPGSGQIQLWQFLLELLSDS SNSSCITWEGTNGEFKMTDPDEVARRWGERKSKPNMNYDKLSRALRYYYD KNIMTKVHGKRYAYKFDFHGIAQALQPHPPESSLYKYPSDLPYMGSYHAH PQKMNFVAPHPPALPVTSSSFFAAPNPYWNSPTGGIYPNTRLPTSHMPSH LGTYYLEESGGGGSPGRRRRRRRRRRR
-
分子量
59 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of ERG (ETS-related gene) fusion proteins has gained significant attention in cancer research, particularly in prostate cancer. ERG, a member of the ETS transcription factor family, is often implicated in the development and progression of various malignancies, predominantly through chromosomal rearrangements leading to the fusion of ERG with other genes, such as TMPRSS2. These fusion events manifest in approximately half of prostate cancer cases, making ERG a critical biomarker for diagnosis and prognosis. The expression of ERG fusion proteins has been associated with aggressive tumor behavior and resistance to standard therapies, underscoring the need for targeted treatment strategies. Additionally, understanding the molecular mechanisms by which ERG influences oncogenic pathways can unveil new therapeutic targets and improve patient outcomes. Research in this domain not only focuses on characterizing the functional implications of ERG fusions but also explores potential inhibitors that could mitigate the oncogenic effects of these proteins. As a result, the exploration of ERG as a therapeutic target is an evolving field, promising advancements in personalized medicine for patients harboring these specific genetic alterations.
